Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 347-348

  Fürstenberger, Gregor ^a   Schmid, Peter ^b   Duquesne, Ans ^b   Ammann, Maria ^c   Senn, Hans Jörg ^a  

^a Tumor Center ZeTuP   (Switzerland)

^b Institute of Radiology RIS   (Switzerland)

^c Institute of Pathology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CHROMOGRANIN A; PENTETREOTIDE IN 111;

ABDOMINAL PAIN; ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; DRY SKIN; HUMAN; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHROMOGRANIN A; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36349032247     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0590-9     Document Type: Article

References (4)

1. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637-642
2. Yalcin S, Oyan B, Bayraktar Y (2007) Current medical treatment of pancreatic neuroendocrine tumors. Hepatogastroenterology 54:278-284 (Review)
3. Yao J, Hoff P, Phan T, Hess K (2005) Improved progression free survival (PFS) and rapid sustained decreased perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol Supp 23(16S):4007 (Abstract)
4. Strosberg JR, Kvols LK (2007) A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 16:219-224 (Review)